Aurinia Pharmaceuticals (AUPH) Received its Third Buy in a Row


After H.C. Wainwright and Cantor Fitzgerald gave Aurinia Pharmaceuticals (NASDAQ: AUPH) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Justin Kim maintained a Buy rating on Aurinia Pharmaceuticals yesterday. The company’s shares closed last Monday at $11.34.

Kim has an average return of 43.6% when recommending Aurinia Pharmaceuticals.

According to TipRanks.com, Kim is ranked #1654 out of 6127 analysts.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $26.00, a 127.1% upside from current levels. In a report issued on March 6, H.C. Wainwright also maintained a Buy rating on the stock with a $32.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $21.93 and a one-year low of $3.52. Currently, Aurinia Pharmaceuticals has an average volume of 1.89M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Read More on AUPH:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts